Provided by Tiger Trade Technology Pte. Ltd.

Tango Therapeutics Inc.

19.73
-0.1350-0.68%
Volume:196.22K
Turnover:3.93M
Market Cap:2.81B
PE:-22.55
High:20.41
Open:19.95
Low:19.64
Close:19.86
52wk High:21.82
52wk Low:1.03
Shares:142.69M
Float Shares:59.76M
Volume Ratio:0.47
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8746
EPS(LYR):-0.8746
ROE:-37.23%
ROA:-19.45%
PB:8.13
PE(LYR):-22.55

Loading ...

Press Release: Tango Therapeutics Appoints Sung Lee to Board of Directors

Dow Jones
·
Jan 05

Tango Therapeutics CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 17, 2025

Tango Therapeutics (TNGX): Assessing Valuation Following New Equity Offering and Shelf Registration Moves

Simply Wall St.
·
Nov 22, 2025

13D Filings -- Barrons.com

Dow Jones
·
Nov 22, 2025

BRIEF-Tango Therapeutics Files Prospectus For Resale Of 1.7 Million Shares By Selling Stockholder - SEC Filing

Reuters
·
Nov 21, 2025

Tango Therapeutics files to sell 1.73M shares of common stock for holders

TIPRANKS
·
Nov 21, 2025

Tango Therapeutics : Sales Agreement Covering Offering of up to $100 Mln Common Stock That May Be Issued From Time to Time

THOMSON REUTERS
·
Nov 21, 2025

Tango Therapeutics Inc - Files Prospectus for Resale of 1.7 Mln Shares by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
Nov 21, 2025

Tango Therapeutics initiated with a Peer Perform at Wolfe Research

TIPRANKS
·
Nov 18, 2025

Will Tango Therapeutics' (TNGX) Return to Profitability Shift Its Investment Narrative?

Simply Wall St.
·
Nov 18, 2025

Trump pardons British billionaire Joe Lewis

Reuters
·
Nov 13, 2025

Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

GlobeNewswire
·
Nov 12, 2025

Tango Therapeutics (TNGX) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Nov 05, 2025

Stock Track | Tango Therapeutics Plummets 5.74% Despite Positive Q3 Results and Extended Cash Runway

Stock Track
·
Nov 04, 2025

Tango Therapeutics reports Q3 net income, revenue jumps

Reuters
·
Nov 04, 2025

Earnings Flash (TNGX) Tango Therapeutics Posts Q3 EPS $0.14, vs. FactSet Est of $0.35 Loss

MT Newswires Live
·
Nov 04, 2025

Tango Therapeutics' September 30 $152.8M In Cash, Cash Equivalents And Marketable Securities, in addition to $212M In October Financing Is Expected To Extend Cash Runway Into 2028

Benzinga
·
Nov 04, 2025

BRIEF-Tango Therapeutics Q3 Basic EPS USD 0.14

Reuters
·
Nov 04, 2025

Tango Therapeutics Q3 Net Income USD 15.884 Million

THOMSON REUTERS
·
Nov 04, 2025

Tango Therapeutics Q3 Operating Expenses USD 39.739 Million

THOMSON REUTERS
·
Nov 04, 2025